Edition:
India

Illumina Inc (ILMN.OQ)

ILMN.OQ on NASDAQ Stock Exchange Global Select Market

243.55USD
19 Jan 2018
Change (% chg)

-- (--)
Prev Close
$243.55
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
318,640
52-wk High
$248.81
52-wk Low
$156.51

Chart for

About

Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of... (more)

Overall

Beta: 0.74
Market Cap(Mil.): $29,871.53
Shares Outstanding(Mil.): 146.30
Dividend: --
Yield (%): --

Financials

BRIEF-Illumina Sees Non-GAAP Diluted EPS Attributable To Illumina Stockholders In Range Of $4.50-$4.60 For Fiscal Year 2018

* ILLUMINA INC - SEES NON-GAAP DILUTED EPS ATTRIBUTABLE TO ILLUMINA STOCKHOLDERS IN RANGE OF $4.50 - $4.60 FOR FISCAL YEAR 2018

11 Jan 2018

BRIEF-Guangzhou Kingmed Diagnostics' Unit Signs Agreement With U.S. company Illumina

Jan 8 Guangzhou Kingmed Diagnostics Group Co Ltd :

08 Jan 2018

BRIEF-HTG Molecular, Illumina Agreed To Third Development Plan Under Parties' Amended & Restated Development & Supply Agreement

* HTG MOLECULAR DIAGNOSTICS - ON DEC 23, CO, ILLUMINA AGREED TO THIRD DEVELOPMENT PLAN UNDER PARTIES' AMENDED & RESTATED DEVELOPMENT & SUPPLY AGREEMENT

28 Dec 2017

BRIEF-Luna Dna Announces $2 Mln In Seed Funding Round Included Several Individual Investors And Former Executives From Illumina

* LUNA DNA ANNOUNCES $2 MILLION IN SEED FUNDING; ROUND INCLUDED SEVERAL INDIVIDUAL INVESTORS AND FORMER EXECUTIVES FROM ILLUMINA Source text for Eikon: Further company coverage:

19 Dec 2017

BRIEF-Disney Board Elects Oracle And Illumina CEOs As Directors

* DISNEY BOARD ELECTS ORACLE’S SAFRA CATZ AND ILLUMINA’S FRANCIS A. DESOUZA AS DIRECTORS

08 Dec 2017

BRIEF-Illumina wins infringement suit against Premaitha Health and Ariosa Diagnostics

* Illumina wins infringement suit against Premaitha Health and Ariosa Diagnostics

22 Nov 2017

BRIEF-Illumina announces ‍introduction of its NextSeq 550Dx instrument

* Illumina Inc - ‍introduction of its NextSeq 550Dx instrument, co's second FDA-regulated and CE-IVD marked next-generation sequencing (NGS) system​

15 Nov 2017

BRIEF-Illumina reports Q3 GAAP earnings per share $1.11

* Illumina reports financial results for third quarter of fiscal year 2017

25 Oct 2017

BRIEF-Illumina files new patent infringement suit against Premaitha Health Plc

* Illumina Inc - ‍filed new patent infringement suit against Premaitha Health Plc in High Court of Justice, Chancery Division, Patents Court in UK Source text for Eikon: Further company coverage:

07 Sep 2017

'Liquid biopsy' spots early-stage cancers in blood: U.S. study

CHICAGO A test that scans blood for tumor-specific DNA identified early-stage cancer in more than half of 138 patients with the disease, U.S. researchers reported on Wednesday, marking a new milestone in the rush for so-called "liquid biopsies."

17 Aug 2017

Earnings vs. Estimates